Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Radiotherapy

Radioactive somatostatin analog therapy against carcinoids

Nature Reviews Endocrinology volume 6, pages 428–430 (2010)Cite this article

Subjects

A recent article by Bushnell et al. confirms and reassures what neuroendocrine tumor specialists have witnessed and believed for some time: radionuclide therapy using somatostatin analogs labeled with radioactive yttrium-90 alleviates symptoms of metastatic neuroendocrine tumors, reduces or stabilizes tumor burden and improves quality of life.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bushnell, D. L. et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652–1659 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Van Essen, M., Krenning, E. P., De Jong, M., Valkema, R. & Kwekkeboom, D. J. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs in patients with somatostatin receptor positive tumors. Acta Oncol. 46, 723–734 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Warner, R. R. Carcinoid case presentation and discussion: the American perspective. Endocr. Relat. Cancer. 10, 489–496 (2003).

    Article  CAS  PubMed  Google Scholar 

  4. Kvols, L. K. Revisiting C. G. Moertel's land of small tumors. J. Clin. Oncol. 26, 5005–5007 (2008).

    Article  PubMed  Google Scholar 

  5. Oberg, K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 (Suppl. 1), 92–97 (2000).

    Article  CAS  PubMed  Google Scholar 

  6. Chan, J. A. & Kulke, M. H. Progress in the treatment of neuroendocrine tumors. Curr. Oncol. Rep. 11, 193–199 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Phan, A. T. & Yao, J. C. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology 22, 1617–1623 (2008).

    PubMed  Google Scholar 

  8. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130 (2008).

    Article  CAS  PubMed  Google Scholar 

  9. Delpassand, E. S. et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother. Radiopharm. 23, 292–300 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, B-131, 8700 Beverly Boulevard, Los Angeles, 90048, CA, USA

    Run Yu

Authors
  1. Run Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, R. Radioactive somatostatin analog therapy against carcinoids. Nat Rev Endocrinol 6, 428–430 (2010). https://doi.org/10.1038/nrendo.2010.94

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2010.94

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing